Overall survival in HER2-negative patients: pooled
analysis of studies 305 and 301
Hazard ratio stratified by region, prior capecitabine use and study
Overall survival curves adjusted by study
305 study data is updated 77% event analysis
Time (months)
12 14 16 18 20 22 24
58
10
8
6
4
2
0
480
331
545
372
603
420
664
470
712
531
748
572
108
91
91
77
130
101
155
118
188
142
223
162
324
220
264
183
393
256
442
284
2
1
0
0
2
2
8
9
6
2
12
10
13
11
Number of subjects at risk
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56
20
16
16
13
25
17
39
28
27
21
54
43
71
56
Median OS
(months)
Eribulin (n=748)
15.2
Control (n=572)
12.3
HR
0.819
95% CI
0.722, 0.929
P value
0.0019
2.9 months
difference
Proportion of survival
